OSTX Overview

OS Therapies Incorporated is a clinical-stage oncology company focused on the identification, development, and commercialization of new class immunotherapy candidates for solid tumors, beginning with osteosarcoma and other solid tumors. Its pipeline includes two drug technologies: OST-HER2 and OST-tADC. Its lead asset, OST-HER2, is an off-the-shelf immunotherapy, which is a type of cancer treatment that helps one’s immune system fight cancer, comprised of a genetically weakened and modified strain of Listeria monocytogenes, a species of bacteria that causes the infection listeriosis, that expresses HER2 peptides. OST-tADC is a tunable ADC with a plug-and-play platform that features tunable pH-sensitive silicone linkers (SiLinkers). Its clinical-stage cancer immunotherapy programs also include OST-AXAL for human papilloma virus (HPV)-associated cancers; OST-503 for non-small cell lung cancer (NSCLC) & glioblastoma; and OST-PSA for prostate cancer.

Wall Street analysts forecast OSTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OSTX is11.50 USD with a low forecast of 6.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

OS Therapies Inc revenue for the last quarter amounts to -6.88M USD, increased 182.25

OS Therapies Inc. EPS for the last quarter amounts to -4706192.00 USD, increased 39.04

OS Therapies Inc (OSTX) has 4 emplpoyees as of March 12 2026.

Today OSTX has the market capitalization of 54.58M USD.